Title: Lower end of treatment HBsAg and HBcrAg were associated with HBsAg loss after
nucleos(t)ide analog cessation
Version: 1 Date: 30 Mar 2023
Reviewer's report:
1. Follow-up of 24 months was short, but the overall quality of this paper is good.
2. Please confirm whether there is a description of liver stiffness value in the admission criteria
of patients.
3. in the last paragraph of discussion, “HBeAg-positive patients with HBsAg # 135 IU/mL
or HBcrAg # 3.6 logU/mL stopping NA treatment may have more chance to be off-treatment
HBsAg loss" is not an appropriate description, because a small number of e antigen positive
patients may have low levels of HBsAg, less than 135 IU/mL, but obviously cannot be
discontinued of NAs.
4. It is worth discussing whether the relevant description of "patient signing informed consent"
is required.
Title: Lower end of treatment HBsAg and HBcrAg were associated with HBsAg loss after
nucleos(t)ide analog cessation
Version: 1 Date: 30 Mar 2023
Reviewer's report:
1. Follow-up of 24 months was short, but the overall quality of this paper is good.
2. Please confirm whether there is a description of liver stiffness value in the admission criteria
of patients.
3. in the last paragraph of discussion, “HBeAg-positive patients with HBsAg # 135 IU/mL
or HBcrAg # 3.6 logU/mL stopping NA treatment may have more chance to be off-treatment
HBsAg loss" is not an appropriate description, because a small number of e antigen positive
patients may have low levels of HBsAg, less than 135 IU/mL, but obviously cannot be
discontinued of NAs.
4. It is worth discussing whether the relevant description of "patient signing informed consent"
is required.
Please review this paper.
user
Title: Lower end of treatment HBsAg and HBcrAg were associated with HBsAg loss after
nucleos(t)ide analog cessation
Version: 1 Date: 30 Mar 2023
Reviewer's report:
1. Follow-up of 24 months was short, but the overall quality of this paper is good.
2. Please confirm whether there is a description of liver stiffness value in the admission criteria
of patients.
3. in the last paragraph of discussion, “HBeAg-positive patients with HBsAg # 135 IU/mL
or HBcrAg # 3.6 logU/mL stopping NA treatment may have more chance to be off-treatment
HBsAg loss" is not an appropriate description, because a small number of e antigen positive
patients may have low levels of HBsAg, less than 135 IU/mL, but obviously cannot be
discontinued of NAs.
4. It is worth discussing whether the relevant description of "patient signing informed consent"
is required.
assistant